Supernus Pharmaceuticals Inc (SUPN) Expected to Announce Quarterly Sales of $104.35 Million

Share on StockTwits

Equities analysts expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to post sales of $104.35 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Supernus Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $99.30 million and the highest estimate coming in at $111.05 million. Supernus Pharmaceuticals reported sales of $90.43 million during the same quarter last year, which would suggest a positive year over year growth rate of 15.4%. The firm is scheduled to report its next earnings report on Tuesday, May 14th.

On average, analysts expect that Supernus Pharmaceuticals will report full year sales of $455.79 million for the current year, with estimates ranging from $450.79 million to $460.62 million. For the next year, analysts expect that the company will post sales of $545.80 million, with estimates ranging from $536.56 million to $555.83 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, February 26th. The specialty pharmaceutical company reported $0.48 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.19. Supernus Pharmaceuticals had a return on equity of 27.45% and a net margin of 27.14%. The firm had revenue of $113.50 million for the quarter, compared to the consensus estimate of $105.36 million. During the same quarter in the previous year, the business earned $0.26 EPS. The company’s quarterly revenue was up 31.4% compared to the same quarter last year.

A number of analysts have weighed in on the company. Zacks Investment Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating and set a $46.00 price objective for the company in a research report on Saturday, March 2nd. Cantor Fitzgerald set a $57.00 price target on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, December 14th. B. Riley set a $65.00 price target on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, March 4th. ValuEngine downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 6th. Finally, Cowen set a $55.00 price target on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a report on Friday, November 30th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $55.75.

Shares of NASDAQ SUPN traded down $0.76 during mid-day trading on Monday, hitting $37.74. The stock had a trading volume of 21,409 shares, compared to its average volume of 630,979. The company has a quick ratio of 2.90, a current ratio of 3.06 and a debt-to-equity ratio of 0.73. Supernus Pharmaceuticals has a 1 year low of $30.05 and a 1 year high of $61.25. The company has a market cap of $2.01 billion, a price-to-earnings ratio of 18.41 and a beta of 1.62.

In other news, CFO Gregory S. Patrick sold 20,000 shares of Supernus Pharmaceuticals stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $41.53, for a total value of $830,600.00. Following the completion of the transaction, the chief financial officer now owns 67,896 shares of the company’s stock, valued at approximately $2,819,720.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.20% of the stock is owned by insiders.

A number of large investors have recently modified their holdings of the business. Menta Capital LLC increased its position in shares of Supernus Pharmaceuticals by 3.5% during the 4th quarter. Menta Capital LLC now owns 7,824 shares of the specialty pharmaceutical company’s stock valued at $260,000 after purchasing an additional 265 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Supernus Pharmaceuticals by 4.1% during the 4th quarter. Victory Capital Management Inc. now owns 7,536 shares of the specialty pharmaceutical company’s stock valued at $250,000 after acquiring an additional 296 shares during the period. Advisor Group Inc. grew its stake in shares of Supernus Pharmaceuticals by 17.2% during the 4th quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock valued at $69,000 after acquiring an additional 306 shares during the period. Mizuho Securities USA LLC grew its stake in shares of Supernus Pharmaceuticals by 3.4% during the 4th quarter. Mizuho Securities USA LLC now owns 12,000 shares of the specialty pharmaceutical company’s stock valued at $399,000 after acquiring an additional 400 shares during the period. Finally, Piedmont Investment Advisors Inc. grew its stake in shares of Supernus Pharmaceuticals by 3.4% during the 4th quarter. Piedmont Investment Advisors Inc. now owns 12,377 shares of the specialty pharmaceutical company’s stock valued at $411,000 after acquiring an additional 409 shares during the period. 97.89% of the stock is owned by institutional investors and hedge funds.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Further Reading: Is a Roth IRA right for you?

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply